Download PDF
TumorDiagnostik & Therapie 2011; 32(06): 333-337
DOI: 10.1055/s-0031-1281830
Thieme Onkologie aktuell
© Georg Thieme Verlag KG Stuttgart · New York ·

Epigenetische Modifikationen in malignen Zellen

Relevanz für die Therapie von myelodysplastischem Syndrom und akuter myeloischer LeukämieEpigenetic changes in malignant cellsRelevance for the treatment of myelodysplastic syndrome and acute myeloic leukemia
B. Hackanson
,
M. Lübbert
Further Information

Publication History

Publication Date:
12 December 2011 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Abstract

Schlüsselwörter

Epigenetik - DNA-Methylierung - Histone

Key words

epigenetics - DNA methylisation - histones
 

  • Literatur

  • 1 Almstedt M, Blagitko-Dorfs N, Duque-Afonso J et al. The DNA demethylating agent 5-aza-2´- deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res 2010; 34: 899-905
    CrossrefPubMedGoogle Scholar
  • 2 Borthakur G, Ahdab SE, Ravandi F et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008; 49: 690-695
    CrossrefPubMedGoogle Scholar
  • 3 Cashen AF, Schiller GJ, O'Donnell MR et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. Clin Oncol 2010; 28: 556-561
    CrossrefPubMedGoogle Scholar
  • 4 Fenaux P, Mufti GJ, Hellström-Lindberg E et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569
    CrossrefPubMedGoogle Scholar
  • 5 Fenaux P, Mufti GJ, Hellström-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232
    CrossrefPubMedGoogle Scholar
  • 6 Field T, Perkins J, Huang Y et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010; 45: 255-260
    CrossrefPubMedGoogle Scholar
  • 7 Flotho C, Claus R, Batz C et al. The DNA methyltransferase inhibitors azacitidine, Decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009; 23: 1019-1028
    CrossrefPubMedGoogle Scholar
  • 8 Garcia-Manero G, Yang H, Bueso-Ramos C et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-1066
    PubMedGoogle Scholar
  • 9 Goodyear O, Agathanggelou A, Novitzky-Basso I et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010; 116: 1908-1918
    CrossrefPubMedGoogle Scholar
  • 10 Hackanson B, Guo Y, Lübbert M. The silence of the genes: epigenetic disturbances in haematopoietic malignancies. Expert Opin Ther Targets 2005; 9: 45-61
    CrossrefPubMedGoogle Scholar
  • 11 Issa JPJ, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009; 15: 3938-3946
    CrossrefPubMedGoogle Scholar
  • 12 Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803
    CrossrefPubMedGoogle Scholar
  • 13 Kornblith AB, Herndon 2nd JE, Silverman LR et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002; 20: 2441-2452
    CrossrefPubMedGoogle Scholar
  • 14 Kuendgen A, Schmid M, Schlenk R et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006; 106: 112-119
    CrossrefPubMedGoogle Scholar
  • 15 Ley TJ, Ding L, Walter MJ et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433
    CrossrefPubMedGoogle Scholar
  • 16 Lübbert M, Bertz H, Rüter B et al. Non-intensive treatment with low-dose 5-aza-2´- deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009; 44: 585-588
    CrossrefPubMedGoogle Scholar
  • 17 Lübbert M, Suciu S, Baila L et al. Low-dose decitabine vs. best supportive care in elderly patients with intermediate- or high-risk MDS ineligible for intensive chemotherapy: final results of the randomized phase III study of the EORTC Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; in press
    PubMedGoogle Scholar
  • 18 Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011; 29: 475-486
    CrossrefPubMedGoogle Scholar
  • 19 Möller I, Blum S, Gattermann N et al. Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine. Ann Hematol 2009; 88: 1141-1144
    CrossrefPubMedGoogle Scholar
  • 20 Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440
    CrossrefPubMedGoogle Scholar
  • 21 Wagner J, Hackanson B, Lübbert M et al. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenet 2010; 1: 117-136
    CrossrefPubMedGoogle Scholar